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INTRODUCTION 
Several chemical mediators play an important role 
in the normal functioning of the respiratory system in 
man, in addition to the expression of the immune response. 
These mediators include histamine, prostaglandins, kalli- 
krein, eosinophil chemotactic factor of anaphylaxis 
(ECF-A), slow-reacting factor of anaphylaxis (SRS-A), 
and platelet-activating factor (PAF). All may be released 
by normal respiratory tissue after passive sensitization 
with IgE antibody and challenge with specific anti¬ 
gen (8) . 
Mediators may be released from cells such as mast 
cells and basophils in response to a number of immuno¬ 
logic or non-specofic stimuli. Airway-constricting 
stimuli include histamine, cholinergic agonists, SRS-A, 
bradykinin, prostaglandin F 2oc» 3-adrenergic blocking drugs , 
cold air, dust, sulfur dioxide, exercise, and suggestion 
(15)• In addition to their role in normal physiologic 
processes, mediators play an important role in the patho¬ 
genesis of disease states such as asthma and the anaphyl¬ 
actic response. 
The following pages will focus on histamine, a 
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well-investigated mediator. The actions and role of 
histamine in both the normal and pathologic setting 
will be addressed. There will be particular focus on 
the presence of histamine in the respiratory system. 
The final chapter includes an original investigation 
of the presence of histamine receptors in the airways 
of healthy, human subjects. 
HISTAMINE 
Background and History 
Histamine, 3-imidazolylethylamine, was first 
synthesized in the laboratory in 1907. Ln vivo, it 
is formed by the decarboxylation of L-histidine, by 
histidine decarboxylase. Histamine was first isolated 
in bacteria in 1910 and was one of the first vaso¬ 
active substances to be identified (42, 43). The 
name is derived from the Greek word histos, meaning 
tissue. 
Histamine is stored in mast cells in various 
tissues as well as in basophils in blood. The mast 
cell, which also contains heparin, is the major reposi¬ 
tory for histamine. Histamine is also present in as 
yet unidentified non-mast cells of the gastric and 
intestinal mucosa and the brain. In the rabbit (12), the 
bulk of histamine in the blood is stored in the platelets. 
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Histamine is released in response to various 
immunological stimuli as in IgE-antigen-mediated immune 
reactions (lL). It is also released in response to 
nonimmunological stimuli such as trauma, toxins, or 
suggestion (131)- The liberation of histamine by cells 
in response to injurious stimuli was noted as early as 
1Q27 by Lewis (52). Mast cell liberators, such as dextran 
and anaphylatoxin, may also release histamine. 
During the release of histamine from mast cells, 
the mast cell degranulates. The histamine stored in the gran¬ 
ule, along with other preformed and stored mediators, is ex- 
pulsed from the cell and is followed by release of 
histamine from a heparin-protein complex (12). A highly 
polar molecule at physiologic pH, histamine does not 
diffuse across the blood-brain barrier or cell membranes. 
The action of histamine is rapid. It quickly 
diffuses into tissues and is rapidly metabolized. Gut 
flora in man converts ingested histamine to the inactive 
N-acetylhistamine (52). Once released, histamine will 
disappear from the blood stream within minutes. 
Histamine and Its Receptors 
Histamine exerts its effects through interaction 
with at least two identifiable receptors, which are 
referred to as Ha and H2 receptors. These receptors 
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may be preferentially blocked by specific antihistamines 
The Hi class of antihistamines are referred to as the 
"classical antihistamines". The first antihistamines 
to be developed, Bovet and Staub discovered the first 
Hi antihistamines in 1937* The structure is of the form 
AriVs' X —C — C — CH3 
\ CH3 
where X may be C, 0, or N, Ari and Ar2 are aromatic or 
aryl ring structures and N must be charged at physio¬ 
logic pH. Antihistamines act by competitive and re¬ 
versible occupation of histamine receptor sites without 
themselves initiating a response. 
Ash and Schild (6) were the first to demonstrate 
the presence of more than one class of histamine recep¬ 
tor. They demonstrated that several effects of hista¬ 
mine, such as stimulation of gastric secretion and 
inhibition of rat uterus contractions could not be 
suppressed by classical antihistamines. 
Black, _et al. (18) were the first to develop 
burimamide, an H2 receptor antagonist. It was noted 
that while burimamide did not have any significant Hi 
receptor antagonism, it successfully prevented gastric 
acid secretion. 
Further evidence for the existence of two separate 
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classes of histamine receptors has come from the syn¬ 
thesis of agonists specific to Ha and H2 receptors. 
For example, while 2-methylhistamine can elicit the Hi 
effect of stimulating bronchial contraction, it has no 
significant effect on gastric acid secretion. On the 
other hand, 4-methylhistamine can increase gastric acid 
secretion, but has little effect on airway constriction 
(52). In one study (18), 2-methylhistamine was shown 
to have 16.5$ of the Hi activity of histamine as 
measured by ability to constrict guinea pig terminal 
ileum. Its H2-mediated ability to stimulate isolated 
atrium was only 4.4%. While 4-methyhistamine had 43% 
of the ability of histamine to stimulate the guinea 
pig isolated atria, the relative activity on terminal 
ileum was only 0.23%. 
Other Hi agonists include 2-(2-aminoethyl)-pyridine 
and 2-(2-aminoethyl)-thiazole (125). Other H£ agonists 
are clonidine (7), St 600 ([2-(5~flouro-o-toluidine)-2 
imidazoline hydrochloride])(27), and dimaprit ([S-[3- 
(N,N-dimethyamino)propyl]isothiourea])(121). 
THE ACTIONS AND ROLE OF HISTAMINE AND 
ANTIHISTAMINES IN PHYSIOLOGIC PROCESSES 
Histamine was recognized a half-century ago (11) 
as being involved in the inflammatory response and 
allergic phenomena. The "classic" histamine response 
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in man includes itching, swelling, redness (histamine 
flush), headache, and bronchoconstriction. Histamine 
will elicit the cutaneous "triple response" of a red 
spot and flush, wheal, and itch--symptoms which are 
associated with the inflammatory response and anaphyl¬ 
axis. The following are brief outlines of some other 
actions of histamine, with emphasis, where possible, 
of the pharmacologic effects of histamine and anti¬ 
histamines in man. The role of histamine in the immune 
response and pathologic processes will be dealt with in 
greater detail in a subsequent chapter. 
Respiratory System 
In man, large concentrations of histamine have the 
primary effect of bronchoconstriction. Histamine causes 
an increase in respiratory air resistance and a decrease 
in airway compliance (8). Other animal species may 
exhibit either bronchoconstriction, bronchodilation, 
or both in response to histamine. The response will 
be determined by which part of the respiratory system 
is stimulated, which specific receptors are agonized, 
and what are the effects of those specific receptors. 
This will be examined in a forthcoming section. 
Circulatory System 
As in the respiratory system, vasodilation or 
vasoconstriction will be the effect of histamine agonism, 
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and will vary depending upon the size and location of 
the blood vessel, the classification of histamine recep¬ 
tor which is being agonized, as well as the species 
involved. In man, histamine will cause constriction 
of large arteries and veins and dilation of the smallest 
vessels to contain smooth muscle. Intravenous hist¬ 
amine in man, cats, dogs, and sheep will cause a fall 
in systemic blood pressure secondary to peripheral 
vasodilation (1, 19). 
In cats, dogs, and chickens, the blood vessels 
dilate in response to both Hi and H2 agonism (19. 34, 
1^5). In rabbit blood vessels, Ha agonism causes 
vasoconstriction and H2 agonism causes vasodilation (34). 
The reverse is the case for calves (34, 66). 
In man, peripheral vasodilation is mediated by 
both Ha and H2 receptors (l4, 99)- Combinations of Hi 
and H2 antagonists are more successful in preventing 
the effects of histamine on skin (101) and the cardio¬ 
vascular system (13)* than use of any one antagonist 
alone. 
Vasodilation in the cerebral blood vessels in man 
accounts for histamine-induced headache. 
Histamine's evanescent effect on small blood 
vessel dilation leads to enhancement of the body's 
microcirculation, which is due, in part, to the con- 
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tinuous alternating vasodilation and vasoconstriction 
caused by changing concentrations of histamine. Hist¬ 
amine will increase capillary permeability with the 
resultant effect of formation of edema, increased blood 
viscosity, and hemoconcentration. 
The effect on the heart is to stimulate cardiac 
contractility. Histamine will also increase the rate 
of cardiac contraction, and will decrease AV-node con¬ 
duction. In vitro studies of the guinea pig heart (92) 
show that Hi receptors may be involved in mediation of 
a negative dromotropic effect, an atrial inotropic 
effect, and promotion of histamine-induced arrythmias 
of conduction. H2 receptors mediate positive chrono¬ 
tropic effects, ventricular inotropic effects, and 
promote histamine-induced arrythmias of automaticity. 
Histamine will constrict smooth muscle of the 
spleen. 
Endocrine system 
The adrenal medulla will release catecholamines 
in response to histamine. 
Tissue Growth and Repair 
Histamine is found in increased concentration in 
areas of wound repair. Increased levels of histamine 
may be found in regenerating liver, granulation tissue, 
and the fetus. Tissue damage through local irritants 
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will increase histidine decarboxylase activity at the 
site on injury, leading to increased histamine levels 
(12). Histamine promotes wound healing as well as the 
formation of keloids and scar tissue. It also helps 
to provide an increased blood supply to areas of injury. 
Gastrointestinal system 
Acting through stimulation of H2 receptors, 
histamine stimulates gastric acid secretion by the 
parietal cells of the stomach. H2 receptor blockade, 
in addition to blocking gastric acid secretion, also 
blocks the effects of gastrin and pentagastrin. This 
finding suggests that histamine may act as a final 
"common messenger" for several hormones in the gastric 
mucosa (34). Histamine may also stimulate, via H2 
receptors, pancreatic secretion and cholecystokinesis 
( 34). It will also contract smooth muscle of the gut 
via Ha receptor stimulation. 
Nervous system 
The function of histamine in the brain remains 
obscure, although its presence has been demonstrated 
in a variety of structures. The binding of radio¬ 
active H2 antagonists has been demonstrated in guinea 
pig midbrain, cortex, hippocampus, thalamus, brainstem, 
hypothalamus, cerebellum, and corpus striatum (23)- 
Histamine has been isolated in rat, mouse, and monkey 
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hypothalamus as well as midbrain, cortex, and cerebellum 
(13)* Histamine agonism with the H2 receptor increases 
levels of cyclic AMP in these structures (l4). 
Histamine stimulates sensory nerve endings, pro¬ 
ducing pruritis. Histamine may facilitate ganglionic 
transmission via Ha agonism. H2 receptors may inhibit 
ganglionic transmission. 
Urinary system 
Histamine has a dual mode of action in the human 
kidney. It causes a pressor response on renal vascu¬ 
lature via Ha agonism and a depressor response via H2 
agonism. 
Hi Antihistamines 
Hi antihistamines, which include chlorpheniramine, 
diphenhydramine, and mepyramine, are of therapeutic 
use in seasonal rhinitis, allergic dermatoses, itching 
pruritides, hay fever, insect bites, ivy poisoning, 
blood transfusion reactions, serum sickness, allergic 
reactions to drugs, Menibre's disease, and vertigo (13- 
52). They inhibit the histamine-induced increase in 
capillary permeability during anaphylaxis. Hi anti¬ 
histamines do not completely block anaphylaxis in man 
because of the significant contribution of several other 
mediators. 
Hi antihistamines may also cause somnolence, 
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prevent motion sickness, provide a mild anticholinergic 
effect, and have a mild anesthetic effect. Because of 
their mild anticholinergic, antiadrenergic, and anti- 
serotonergic activities, the use of Hi antihistamines 
in laboratory investigations has occasionally resulted 
in erroneously ascribing cholinergic, adrenergic, or 
serotonergic effects to histamine. 
Hi antihistamines are metabolized by the liver and 
degradation products are almost completely excreted 
within 24 hours. Tissues are almost totally free of 
Ha. antagonists within 6 hours. 
H2 Antihistamines 
H2 antihistamines have gained recent wide clinical 
use in the treatment of a variety of gastrointestinal 
disorders associated with hypersecretion of gastric 
acid. Of particular significance is the recent popu¬ 
larity of cimetidine in the treatment of duodenal 
ulcers. 
Another class of histamine antagonist is the mast 
cell stabilizer, such as cromolyn sodium. Cromolyn, 
which can also inhibit antigen-induced production of hist¬ 
amine (52), has as its main effect, the prevention of 
release of histamine and SRS-A. Cromolyn sodium does 
not interact directly with either Hi or H2 receptors. 
-11- 

THE PRESENCE AND ROLE OF Hi AND H2 
RECEPTORS IN THE RESPIRATORY SYSTEM 
The laboratory investigation which will be described 
in a forthcoming chapter will examine the presence of 
histamine Hi and H2 receptors in the airways of healthy 
human subjects. The following is a detailed description 
of studies which have investigated the presence of 
histamine receptors in the respiratory systems of a 
variety of species, both in vivo and in vitro. 
Histamine Receptors in Guinea Pig Airways 
Guinea pig trachea may be caused to contract due 
to antigen-induced anaphylaxis (Schultz-Dale phenomenon). 
It was noted almost fifty years ago (11) that these 
contractions are associated with the release of histamine 
from guinea pig lung. The causative effect of histamine 
in producing the contractions has been demonstrated by 
the partial or complete block of these contractions by 
Hi antihistamines (38, 85)- The fact that mepyramine 
only partially prevents antigen-induced contractions 
indicates the presence of other mediators which cause 
tracheal contractility. 
Direct stimulation of guinea pig tracheobronchial 
tissue by histamine results in a profound net smooth 
muscle contraction (52). Mepyramine totally blocks 
histamine-induced contraction (85). Metiamide, which 
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antagonizes H2 receptors, potentiates histamine-induced 
contraction. However, stimulation of Hi receptors by 
the specific Ha agonist, 2-methylhistamine, causes 
constriction which is not potentiated by metiamide (117). 
It can thus be inferred that histamine causes both Hx 
stimulated contraction and H2 stimulated relaxation of 
guinea pig tracheobronchial muscle. Each effect can 
be isolated by use of specific antagonists. 
The Hx constricting effects and H2 relaxing effects 
on guinea pig tracheobronchial muscle can be demonstrated 
indirectly through studies with antihistamines. However, 
more direct evidence is available through observation 
of the effects of histamine agonists. As previously 
mentioned, the effect of 2-methylhistamine is to cause 
tracheobronchial contraction. 
Another Hx agonist is 2-(2-pyridyl)-ethylamine 
(2-PEA). 2-PEA will cause contraction of guinea pig 
tracheal spirals, in vitro. This constriction of tracheal 
spirals and parenchymal strips is reversed by dimaprit, 
an H2 agonist, which mediates relaxation of the smooth 
muscle. The effect of dimaprit may be blocked by 
metiamide ( 5*0 • 
In guinea pig bronchial smooth muscle undergoing 
ovalbumin antigen-induced anaphylactic contractions, 
dimaprit had a significant bronchodilatory effect (32). 
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This effect was even more profound than treatment with an 
Hi antagonist, mepyramine. 
Direct evidence for histamine Hi receptor presence in 
guinea pig lung and other organ systems has come from studies 
which trace histamine receptors by radioactively labelling 
tissues with [3H]-mepyramine (4l). 
Drazan and Schneider (53) found that histamine induced 
constriction in both guinea pig trachea and lung parenchyma. 
They discovered that histamine Hi antagonism by mepyramine was 
more successful in blocking constriction in lung parenchyma 
than in trachea. This suggests that histamine receptors are 
not necessarily distributed evenly in the airways. There 
appears to be a greater number of receptors and/or sensitivity 
to the effects of histamine in peripheral airways in the 
guinea pig. A future study involving radioactively-labelled 
antagonists in different parts of the respiratory system 
would be useful in supporting these findings. 
In addition to the effect of the direct interaction of 
histamine with its receptors, histamine receptor agonism may 
also cause release of prostaglandins. These prostaglandins 
act as additional mediators of airway reactivity, but do not 
act as the final mediators of histamine agonism. The mecha¬ 
nism for release of prostaglandins in response to histamine 
stimulation involves Hi receptor-cyclic GMP stimulated release 
of PGF2a and H2 receptor-cyclic AM? stimulated release of PGE. 
Yen, et al. (156) used the presence of prostaglandins 
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PGF 2a and PGE as an assay for determining the distribution 
of histamine Ha and H2 receptors within the lung. They found 
that the Hi antagonist, pyrilamine, blocked the histamine- 
induced increases in PGF 2CC. Metiamide diminished the 
histamine-induced release of PGE. 
The authors found that in response to histamine in guinea 
pig trachea, PGE was present in much greater concentrations 
than PGF2a. In guinea pig peripheral airways, PGF 2CX was 
present in higher concentrations than PGE (156). The authors 
conclude that there might be more H2 receptors in central than 
peripheral airways. They find this conclusion consistent with 
the physiologic importance of maintaining the patency of 
central airways. The rapid shifts, on the other hand, of 
peripheral airway size through bronchoconstriction, has been 
suggested to maximize ventilation-perfusion ratios (156). 
In additional to prostaglandins, levels of cyclic nucleo¬ 
tides are a useful assay for determining the presence of 
histamine receptors. In guinea pig lung anaphylaxis, the 
antigen-antibody reaction yields an increase in levels of 
cyclic AMP, cyclic GMP, and the ratio of cAMP to cGMP. 
Pyrilamine inhibits histamine stimulated increases in cyclic 
GMP (103). Burimamide had no effect on cGMP but blocked the 
histamine-induced increases in cAMP. 
While there may exist different distributions of 
Hi and H2 receptors within guinea pig airways, Hi and 
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H2 receptors may also differ in sensitivity to histamine. 
Yen (155) showed that in guinea pig peripheral airway 
smooth muscles, concentrations of 10-10- 10-7 M of 
histamine caused bronchorelaxation which was blocked 
by metiamide. Hi receptors had the overwhelming response 
in concentrations of greater than 10"^M of histamine 
with the resultant contraction blocked by chlorphenir¬ 
amine. It appears that H2 receptors are more sensitive 
to histamine than Hx receptors, but in high concentra¬ 
tions, Hi receptors win out, probably because of greater 
numbers. 
The opposite sensitivities to histamine were 
observed by Martin and Fertel (102) in guinea pig 
tracheal rings. They noted that at concentrations of 
5 x lCT-M, guinea pig tracheal rings contracted. However, 
at concentrations of 10-Z+ M of histamine, the tissue 
relaxed. Consistent with these observations was the 
increase in cyclic GMP levels at low histamine concen¬ 
trations. Increased cyclic AMP levels were noted at 
high concentrations of histamine. Thus, in trachea, 
there may be greater sensitivity for Ha receptors, but 
greater numbers of H2 receptors. 
In addition to the presence of histamine receptors 
in guinea pig airway smooth muscle, the presence of 
histamine Hi receptors in guinea pig alveolar macrophages 
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has been demonstrated by both agonist and antagonist 
studies (5°)• 
Histamine Receptors in the Respiratory System of the 
Rat and Ferret: Possible Presence of a Subclass of 
Receptors 
Chand and Eyre (34, 40) have done extensive studies 
on the presence and action of histamine receptors in a 
number of species. They determined that ferret trachea 
and bronchus both constricted in response to histamine 
in vitro. This contraction of smooth muscle was blocked 
by Hi antagonism with mepyramine. Rat trachea did not 
contract in the presence of histamine (40). 
Both rat and ferret trachea and bronchi could be 
made to contract ijn vitro by exposure to carbachol. 
When subsequently exposed to histamine in the presence 
of Hi blockade, the muscles relaxed. This indicates 
that an K2 receptor must have been mediating the tracheo- 
bronchorelaxation, since the Hi receptors were blocked. 
Further evidence comes from studies of direct H2-agonism 
by 4-methylhistamine which also caused relaxation of 
smooth muscle (40). 
It is very interesting to note that the relaxation 
was not blocked by metiamide, burimamide, or cimetidine. 
This important finding suggests the presence of a sub¬ 
class of histamine receptors which are not blocked by 
conventional H2 antagonists, yet are stimulated by 
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4-methylhistamine and produce relaxation of airway 
smooth muscle. The proposed name for this subclass 
of receptors is or H3 receptors. 
More Evidence for Hjstamine3 Receptors: 
The Airways of the Rabbit 
Using a similar methodology for in vitro studies 
as Chand and Eyre (40), Fleisch and Calkins (70) 
ascertained that histamine induces contraction of 
rabbit bronchus. This effect was blocked by Hx 
antagonism with pyrilamine. Interestingly, under 
similar experimental conditions, partially contracted 
rabbit trachea experienced relaxation in the presence 
of histamine. This effect could not be prevented by 
pyrilamine, burimamide, metiamide, indomethacin, or 
propranalol. Thus, histamine-induced tracheal relaxa¬ 
tion does not act through Hi, H2, prostaglandin release 
or 3-adrenergic mechanisms (65. 70). 
Chand and Eyre (36) also found that partially- 
contracted rabbit bronchus relaxed in the presence of 
Hi blockade. This response was not eliminated by 
metiamide. It is thus proposed that rabbit trachea 
(70) and rabbit bronchus (36) may contain H3 receptors 
which mediate smooth muscle relaxation. 
It is important to note that, as in the guinea pig 
the airways of the rabbit experienced different effects 
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of histamine stimulation, depending upon whether central 
or peripheral airways were being agonized. Thus, two 
closely associated tissues in the same system can be 
pharmacologically distinct. It is important, therefore, 
to state specifically which tissues in an airway are 
being stimulated, when analyzing the results of a 
histamine study or when designing an investigation. 
Histamine Receptors in the Horse; A 
Possible Animal Mod el of Human Asthma 
Using their model of carbachol-induced, partially- 
constricted airways, in vitro, Chand and Eyre (37. 39) 
determined that histamine or 2-methylhistamine causes 
tracheobronchial constriction in the horse. Mepyramine 
prevents this histamine-induced contraction. H£ agonists 
such as 4-methylhistamine and dimaprit caused tracheo¬ 
bronchial relaxation in this experimental model. Further 
support of H2 stimulation of muscle relaxation comes 
from treatment of partially-constricted bronchus in 
the presence of Hx blockade. This results in relaxation, 
which could only be the result of H2 receptor agonism. 
The relaxation in horse bronchus was blocked by 
metiamide and burimamide. However, in horse trachea, 
metiamide, cimetidine, and burimamide had no inhibitory 
effect. Perhaps horse trachea also has H3 receptors. 
It has been suggested (39) that the horse may be 
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a good model for human asthma. Horses suffer from 
"broken wind", an obstructive respiratory syndrome, 
also known as equine pulmonary emphysema, which, 
clinically resembles asthma. Thus, the clinical use 
of H2 agonists in asthma may be worth future investi- 
gation. 
Hi blockade is only minimally useful in inhibiting 
anaphylaxis in the sensitized horse (63). As in human 
anaphylaxis, histamine is only one of several mediators 
which are involved in the anaphylactic response in the 
horse. Of importance is the fact that H2 antagonists 
such as metiamide and burimamide potentiate anaphylaxis 
in the horse (39)- H2 antagonists have also been noted 
to exacerbate anaphylaxis in adult domestic fowl and 
the calf (39). The mechanism behind this potentiation 
and its implications in the clinical setting will be 
dealt with in a forthcoming chapter. 
Histamine Receptors in Sheep Airways 
Using burimamide, Eyre was the first to discover 
(14, 6l, 62, 64) the presence of H2 receptors in 
isolated smooth muscle of sheep bronchi. He found that 
histamine causes contraction of trachea and the major 
bronchi in sheep. This effect may be blocked by Hx 
antihistamines. In response to histamine, the lesser 
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bronchi and bronchioles would relax. This effect could 
be blocked by burimamide (14, 64). Intravenous histamine 
results in a net bronchoconstriction in sheep. The net 
effect of inhaled histamine is either bronchodilation 
or minimal bronchoconstriction in the sheep (61, 65). 
Histamine Receptors in Cat Airways 
In i_n vitro cat trachea partially contracted due 
to carbachol, histamine challenge leads to a net broncho¬ 
dilation (14, 62, 64, 100). This effect may be blocked 
by a combination of Hi and H2 antagonists in addition 
to propranalol. This finding suggests, that in the cat 
trachea, histamine acts by both direct action with both 
receptors as well as by indirect action through local 
catecholamine release to produce relaxation. 
The cat bronchus also relaxes in response to 
histamine as well as 2-methylhistamine and 4-methylhist- 
amine (35)- This effect is not reversed, however, by 
either Hi or Hs antagonism, 3-blockade, or prostaglandin 
inhibition, thereby suggesting an H3 mechanism. 
Other investigators (96, 123) found that in the 
cat bronchus, in vitro, histamine challenge caused 
smooth muscle contraction, acting via Hi mechanisms 
which could be blocked by mepyramine. Similarly, 
antigen-induced contraction could be abolished by 
mepyramine in cat bronchial tissue. 
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Histamine Receptors in the Canine Respiratory System 
Histamine causes bronchoconstriction in vivo in 
the dog. When delivered histamine size is greater than 
10 microns, bronchoconstriction is mostly through a 
reflex vagal mechanism. There is a direct effect of 
histamine on smooth muscle receptors if particle size 
is less than 0.5 microns (128). 
Dixon, et al. (51) examined the effect of histamine, 
4-methylhistamine, cimetidine, and chlorpheniramine on 
total lung resistance and dynamic lung compliance in 
anaesthetized dogs. While histamine caused an increase 
in total lung resistance and a decrease in dynamic lung 
compliance, the H2 agonist 4-methylhistamine had no such 
effect. Accordingly, the Ha antagonist, chlorpheniramine 
blocked the effect of histamine, while cimetidine had 
no protective effect. The authors conclude that histamine 
acts mostly through Hi mechanisms in the dog and causes 
airway constriction. Since dynamic lung compliance and 
total lung resistance are particularly useful in 
measuring large airways pulmonary function (°8), perhaps 
this conclusion should not be extended to include the 
peripheral airways of canines. The counterargument is 
that at 0.5 microns in diameter, the histamine particles 
were delivered to the peripheral airways (45). Other 
investigators (5. 33. 83. 132, 153) have found similar 
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in vitro and in vivo evidence in peripheral and central 
airways of dogs. The possibility of regional differences 
in histamine receptor distribution are similarly supported 
by scientific evidence (33)* 
Some investigators (153. 15M have found that 
cimetidine tended to increase airway resistance, 
suggesting a small H2-mediated bronchodilatory effect 
of histamine in the dog lung. On the other hand, 
Irvin and Dempsey (82) find a minor contribution of 
H2-mediated bronchoconsfriction in the peripheral airways 
of dogs. They concur with other authors regarding the 
absence of H2 receptors in canine central airways. 
As in humans, mepyramine does not completely 
block antigen-induced anaphylaxis (33). suggesting the 
role of other mediators such as SRS-A and serotonin in 
this response. Whereas metiamide has been shown to 
exacerbate anaphylaxis in the horse, calf, and domestic 
fowl (39), the H2 antagonist has no such in vivo effect 
in immediate hypersensitivity reactions (33. 153) or 
in vitro models of canine asthma (5. 33)- In ovalbumin- 
sensitized dogs (5), isolated trachealis muscle con¬ 
tracted in response to histamine. This was inhibited 
by pyrilamine. H2 blockade with metiamide had no effect. 
Of interest is the effect of H2 stimulation on 
respiratory secretions, rather than respiratory muscle 
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activity. Cimetidine blocked stimulation of canine 
secretory activity in the lung in histamine-induced 
asthma. Chlorpheniramine also had this effect, but 
to a smaller extent (153)• The investigators conclude 
that histamine acts to promote canine asthma through 
an Hi-mediated muscular effect and an H2-mediated effect 
on secretory activity of the respiratory tract (153- 
154). They propose that H2 antihistamines might have 
therapeutic value in decreasing respiratory secretions 
in the asthmatic. 
Histamine Receptors in the Airways of Rhesus Monkeys 
One published investigation of histamine receptors 
in the airways of rhesus monkeys examined the effect 
of Hi and H2 antagonism on in vivo pulmonary function 
(76). The authors measured peak expiratory flow, total 
pulmonary resistance, dynamic lung compliance, tidal 
volume, and respiratory frequency. 
The results of the study indicated that pretreat¬ 
ment with the Hi antagonist diphenhydramine inhibited 
histamine-induced bronchoconstriction. Metiamide 
potentiated histamine’s bronchoconstrictory effects 
when given prior to histamine challenge (76). Thus, 
this study seems to indicate that histamine causes 
bronchoconstriction in the rhesus monkey via Hi agonism. 
H2 receptors are present and apparently modulate the 
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bronchoconstriction, perhaps via relaxation of smooth 
muscle or by some feedback mechanism. 
Histamine Receptors in the Airways of Man 
There have been a few recent studies which have 
investigated the role of histamine receptors in the 
airways of man. These preliminary reports include 
studies of healthy human subjects as well as human 
asthmatics, who represent a special class of people 
who are exquisitely sensitive to minute quantities of 
histamine. 
Histamine alone causes a net bronchoconstriction 
in man. Normal subjects receiving histamine have been 
reported (110) to experience an increase in respiratory 
system resistance and closing volume and a decrease in 
vital capacity (VC), forced expiratory volume in one 
second (FEVa), and the ratio of FEV i to VC. These 
parameters suggest both large and small airways con¬ 
striction due to histamine. 
Chlorpheniramine clearly prevents histamine- 
induced bronchospasm in children (137) and adults 
(5°. 71. 99)• 
Maconochie, et al. (99) found that in healthy 
subjects, 8 mg. or oral or 5 or 10 mg. of intravenous 
chlorpheniramine generally prevented histamine-induced 
bronchoconstriction, as measured by FEV1. 
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However, 400 mg. or oral cimetidine or 100 or 200 
mg. of intravenous cimetidine blockade of H2 receptors 
had no effect on bronchoconstriction in the subjects 
studied (99). These findings indicate the primary and 
perhaps sole involvement of Hi receptors in histamine- 
induced bronchospasm in healthy, human airways. 
The authors offer (99), as an explanation for the 
lack of effect of cimetidine, the possibility that 
cimetidine did not reach the H2 receptors in the lung 
in sufficient concentrations to produce an effect. 
However, the doses of cimetidine used were adequate to 
inhibit gastric acid secretion and histamine challenge 
did coincide with peak blood levels of cimetidine. 
Eiser (59) was similarly not able to demonstrate 
the presence of H2 histamine receptors in normal human 
airways. He found that H£ blockade with 200 mg. of 
intravenous cimetidine had no effect on histamine-induced 
changes in airway specific conductance in the nine 
subjects tested. 20 mg. of intravenous chlorpheniramine, 
however, significantly shifted the histamine dose-response 
curve to the right. Eiser found no difference between 
chlorpheniramine administration and the administration 
of chlorpheniramine and cimetidine together (59). 
Cimetidine has received wide clinical use since 
its development. In the clinical setting, it does not 
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appear that cimetidine promotes asthmatic bronchospasm (14). 
However, Frith, et al. (71) are preparing a report 
on a study of ten asthmatics. The subjects were selected 
on the basis of histories of episodic dyspnea as well as 
documented reversible airflow destruction. Subjects 
received an increasing dose of inhaled histamine until 
a 20$ drop in FEV i was reached. On subsequent days, 
the same protocol was followed, except subjects were 
pretreated with chlorpheniramine 8 mg. or cimetidine 
600 mg. or both. 
The findings show that Hi blockade significantly 
increased the level of histamine necessary to produce 
a 20$ drop in FEV1 (p=0.0001)(71)• Cimetidine did not 
differ from placebo. However, cimetidine did signi¬ 
ficantly (p=0.04) reduce the effectiveness of chlor¬ 
pheniramine when the two drugs were given together. 
These results indicate the presence of histamine Hi and 
H2 receptors in asthmatic airways, although the H2 
effect does not seem to be very profound. The authors 
do not address the influence of drug-drug interactions 
in their findings. The dose of cimetidine used was 
at least twice that required to reduce food-stimulated 
gastric acid secretion by 50$. 
Nathan, et al. (109) achieved similar results in 
eleven asthmatics. Chlorpheniramine significantly 
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raised (p less than 0.002) the level of histamine 
required to cause a 20 percent drop in FEV1 , a 35 percent 
decline in maximum expiratory flow at 50 percent below 
vital capacity, or a fifty percent decrease in airway 
conductance. Cimetidine significantly decreased the 
amount of histamine necessary to produce these results 
(p less than 0.02). The authors conclude that H2 
receptors, mediating bronchodilation, exist in asthmatic 
airways. 
Pretreatment with aerosolized diphenhydramine in 
adult asthmatics significantly blocked the effects of 
inhaled histamine (28) as measured by the amount of 
histamine required to produce a 20$ drop in FEVi. This 
result lends further support to the theory that histamine 
produces bronchoconstriction by direct action on Hi 
receptor sites. 
Although oral antihistamines are of little clinical 
use in asthmatics, clemastine, an Hi antagonist, when 
delivered directly to the bronchial tree by inhalation 
(113). caused bronchodilation in asthmatics. Pulmonary 
function parameters were FEVa and peak expiratory flow 
rate (PEFR). In addition, the histamine-dose response 
curve was significantly shifted to the right (112). 
These findings wree comparable to the results achieved 
by salbutamol, a @2 receptor agonist. The results of 
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this study may be due to complete blockage of Hi receptors 
in asthmatics, thereby allowing endogenous histamine to 
react specifically with the only unblocked receptors, 
H2 receptors, thereby mediating relaxation in addition 
to the obvious elimination of bronchoconstricting Hi 
activity. An interesting follow-up study would investi¬ 
gate whether cimetidine reverses the bronchodilatory 
effects of inhaled clemastine. 
Dunlop and Smith (57) as well as Kaliner and 
Platshon (89) have provided i_n vitro evidence for the 
presence of histamine receptors in human airways. Dunlop 
and Smith (57) showed, in vitro, in sensitized human 
bronchus, 2-3 mm. in diameter, that in the presence of 
Hi receptor blockade, histamine agonism led to broncho- 
relaxation. This effect could be eliminated by H2 
antagonism with metiamide. Furthermore, in human 
bronchus caused to contract due to exposure to house 
dust mite antigen (57). Ha blockade with mepyramine 
caused decreased contraction while H2 blockade caused 
increased bronchial contraction. 
Kaliner and Platshon (89) demonstrated that 
2-methyhistamine produced an increase in cyclic GMP, 
with subsequent enhancement of mediator release (SRS-A). 
H2 agonism with dimaprit in the human lung caused in¬ 
creased levels of cyclic AMP with subsequent decreased 
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release of SRS-A. This finding indicates that H2 
agonism with substances such as dimaprit might be use¬ 
ful in the treatment of anaphylaxis. 
Histamine's action in asthmatic airways to cause 
bronchoconstriction is almost entirely via direct 
stimulation of smooth muscle receptors (29). In 
asthmatics receiving a dose of atropine, a parasympa¬ 
tholytic drug, at a dose strong enough to achieve 
cholinergic blockade, the histamine dose-response 
curve was slightly shifted to the right (29, 84, 137). 
Thus, in asthmatics, histamine does not act primarily 
through cholinergic pathways. 
Similarly, the vagal-blocker SCK 1000 did not 
prevent histamine-induced bronchospasm in asthmatics 
(150) although it did prevent methacholine-induced 
bronchospasm. Histamine does have some reflex vagal 
nerve irritant receptor action, although this is a 
minor effect (3. 135)* In large airways, it is proposed 
that histamine has more of a reflex vagal effect (8, 47) 
while in small airways, constriction is due to direct 
histamine Hi antagonism. 
As is the case in other species, such as the guinea 
pig and sheep, the distribution and sensitivity of 
histamine receptors may vary in different parts of the 
respiratory system such as in central versus peripheral 
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airways. This possibility makes _in vivo studies in man 
more difficult than in vitro studies. Methodologies 
must deliver histamine to specific parts of the airway. 
Pulmonary function tests must be used to measure constric¬ 
tion or dilation in the specific stimulated sections of 
airway under investigation. Thus, one would not want 
to only measure large airways constriction in a protocol 
where histamine is delivered mostly to the respiratory 
bronchioles. Since large airways have a reflex vagal 
contribution to histamine-induced bronchospasm (47) this 
provides another factor which makes analysis of the presence 
of histamine receptors jjn vivo difficult. 
Pulmonary Vascular Histamine Receptors 
The most profound effect of histamine on airway 
mechanics is by its direct interaction with smooth muscle 
receptors. However, interaction of histamine with 
pulmonary vascular receptors is also very important in 
the regulation of respiration. Studies with a variety of 
results have been performed in a number of animal species. 
In the guinea pig. histamine agonism leads to 
pulmonary vasoconstriction. This effect is most pro¬ 
found in the pulmonary veins (34, 115)* It is proposed 
(64) that histamine-induced pulmonary venospasm may 
increase right atrial pressure and thereby contribute 
to the formation of pulmonary edema. The pulmonary 
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vasoconstriction appears to be mediated by Hi receptors 
in the guinea pig. Burimamide potentiates this response 
Mepyramine has a depressor action on pulmonary vascula¬ 
ture, indicating the presence of H2 receptors which 
mediate pulmonary vasodilation. Some authors feel that 
pulmonary vascular dilation may increase airway re¬ 
sistance, through mechanical obstruction. 
The rat exhibits pulmonary vasoconstriction in 
response to hypoxia. This effect is blocked by meti- 
amide (10) indicating that H2 stimulation leads to 
pulmonary vasoconstriction in the rat. This is the 
opposite effect to be observed in the cat (?9, 145) 
where Hi agonism causes pulmonary constriction and H2 
agonism mediates dilation of pulmonary vasculature. 
Comparable results are available in the dog (74). 
Okpako (116) demonstrated that H2 agonism with 4-methyl- 
histamine had 15 times the vasodepressor potency of 
2-methylhistamine. This vasodepression could be 
abolished by burimamide. 
Tucker, _et al. arrive at similar results in the 
dog (145, 146). Measuring pulmonary vascular resistance 
they found that Hi agonism led to an increase in resis¬ 
tance, while H2 agonism caused a fall in pulmonary 
vascular resistance. Antagonists had the expected 
results of reversal of the effects of agonists. The 
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authors also found (146) that H2 blockade would also 
potentiate pulmonary vasoconstriction during hypoxia. 
Okpako (116) concludes that H2 receptor agonism may 
lead to "pooling of blood" in the bronchial mucosa 
with resultant mechanical obstruction of the airway. 
The effect of histamine on pulmonary vessels seems 
to vary with development in dogs (111). One group of 
authors found that while metiamide potentiated pulmonary 
vasoconstriction in canine pups, this effect disap¬ 
peared after 15 days of life. 
In the horse (77). histamine causes pulmonary 
vasoconstriction. This appears to be mostly an Hi 
effect, although H2 agonism may also contribute to 
vasoconstriction to a lesser degree. In the nonpregnant 
ewe (152), histamine also mediates pulmonary artery 
constriction which may be blocked equally well by Hi 
or H2 antagonists (benadryl and metiamide). 
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THE ROLE OF HISTAMINE IN PATHOLOGIC PROCESSES 
Histamine, Inflammation, and the Allergic Response 
As early as 1910 (42, 43), Dale and Laidlaw 
appreciated the similarities between the effects of 
histamine and anaphylaxis. These include redness, 
swelling, edema, and hypotension. Twenty years later, 
Bartosch at aJL. (11) demonstrated the presence of 
histamine in guinea pig lung during the antigen-antibody 
reaction. 
Sensitized human lung and skin mast cells and leuko¬ 
cytes will release histamine in vitro when challenged 
with specific antigens (1?)- I_n vivo, sensitized humans 
and asthmatics experience increased plasma histamine 
levels following allergen-induced bronchoprovocation 
(17, 28). The increase in histamine levels correlates 
well with the onset of bronchospasm. 
The release is initiated by IgE antibody bound to 
the cell surface. IgE-induced effects are mediated by 
alterations in cyclic nucleotides. 
The fact that a second messenger, in this instance, 
the cyclic nucleotides cAMP and cGMP, may act as the final 
common mediators for the elaboration of the different 
physiological responses of different tissues to antigen- 




So that it is quite possible that 
the production by histamine, and by 
a whole group of other substances, 
of a complex including contraction 
of plain muscle with relaxation and 
permeability of capillaries, may 
depend on a common type of physical 
change in protoplasm produced by all 
of them, the result of which receives 
different expression in terms of the 
physiology of different tissues. 
Mechanisms of Histamine Interaction 
In cells undergoing the IgE mediated antigen- 
antibody reaction (Type I immediate hypersensitivity 
reaction), histamine, acting on Hi receptors, parti¬ 
cipates in an exquisitely fine-tuned mechanism to 
promote the inflammatory process. In addition, hist¬ 
amine also acts on H2 receptors to provide a negative 
feedback on its own actions (3^)- 
Step #1; Histamine Release 
Following the interaction of cell surface-bound 
IgE antibody with specific antigen, there is an in¬ 
flux of extracellular calcium, important for the ini¬ 
tiation of release of histamine-containing granules. 
This is followed by the energy-dependent activation of 
microtubules and microfilaments which results in the 
fusion of the perigranular membrane with the cell 
membrane, followed by exocytosis of granules. Extra¬ 
cellular ions such as sodium then penetrate into the 
granules with the resultant release of the histamine- 
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heparin-protein complex by ion exchange (114). 
Further release of histamine is modulated by intra¬ 
cellular levels of cyclic AMP and cyclic GMP, which, as 
will be seen, are themselves regulated by histamine. 
Platshon and Kaliner (12*0 found that cGMP and cAMP 
levels increased profoundly, simultaneously with the 
appearance of mediators in sensitized human bronchus. 
Hi Receptors Promote the Inflammatory Response 
Acting on Hi receptors, histamine's effect on 
smooth muscle is to facilitate contraction by in¬ 
creasing calcium entry. This leads to depolarization 
and impulse-carrying currents. 
The sudden contraction, which is a result of 
histamine release, is followed by a brief period of 
partial relaxation during the anaphylactic response. 
This is followed by a secondary, sustained contraction, 
which is resistant to classical antihistamines and 
which is attributed to the delayed release of non-hist¬ 
amine mediators such as SRS-A ( 38), 
Cyclic GMP may be implicated in this Hi mediated 
contraction. Increased levels of cyclic GMP are found 
following stimulation with histamine (124). This 
increase may be blocked by Hi antihistamines (124). 
The rise in cyclic GMP is calcium-dependent (14). The 
role of cyclic GMP may be to activate protein kinases 
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which in turn enhance phosphorylation of proteins which 
participate in calcium ion mobilization (14) which in 
turn leads to smooth muscle contraction. 
Histamine seems to promote its own release through 
Hi-mediated positive feedback (14). Hi receptor anti¬ 
histamines inhibit the IgE induced release of histamine 
as well as antigen-induced release of histamine from 
sensitized monkey lung (14). 
Hi receptor agonism enhances eosinophil migration. 
Histamine causes release of prostaglandins from 
the lung. Indomethacin, a prostaglandin synthetase 
inhibitor, diminishes allergic bronchospasm by 40^, 
indicating a role of prostaglandins in allergic broncho- 
constriction, although the prostaglandin synthesis 
which accompanies anaphylaxis has been considered 
secondary to the action of histamine. Suppression of 
prostaglandin synthesis does not prevent hypersensitivity- 
associated rises in cAMP and cGMP. 
The cyclic GMP dependent release of PGF 2CX and 
thromboxane A2, which intensify bronchoconstriction, 
may be inhibited by Ha receptor antagonism with pyri- 
lamine or mepyramine (64, 125). Hi agonism with 
2-methylhistamine promotes release of PGF 2CL and throm¬ 
boxane A2 (16, 124). 
Histamine agonism of Hi receptors (and to a 
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lesser extent H2 receptors) also increases vascular 
permeability. This facilitates the migration of immuno¬ 
globulins and leukocytes to the site of inflammation. 
Hg Receptors Inhibit the Inflammatory Response: 
Potentiation of Anaphylaxis By H2 Receptor Blockade 
Histamine acts through H2 receptors in a different 
manner than Hx receptors. Stimulation of histamine 
H2 receptors causes a rise in cyclic AMP (124). Blockade 
of the H2 receptor prevents a rise in cyclic AMP (2, 
124, 134, 138), except in mice, where Hx and not H2 
receptor blockade prevents histamine-induced cAMP 
accumulation (118). 
Cyclic AMP facilitates calcium sequestration and 
extracellular transport, with resultant relaxation of 
contractile proteins. Elevated levels of cyclic AMP 
correlate with bronchial smooth muscle relaxation 
and bronchodilation. 
Effect on Histamine Release 
H2 receptor agonism and the subsequent rise in 
cyclic AMP is also very important in the regulation 
of the immune process. Elevated levels of cyclic AMP 
inhibit histamine and and SRS-A release from the mast 
cell and human leukocytes (21). 
In humans allergic to ragweed, histamine is re- 
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leased upon exposure to ragweed antigen. In leukocytes of 
these human donors, in vitro, this release of histamine 
may be inhibited by histamine, isoproteronol, or methyl- 
xanthines. Each of these substances acts to increase 
levels of cyclic AMP (21). Lichtenstein and Gillespie 
(94) demonstrated that H2 antagonists could prevent the 
inhibition of histamine release from blood basophils. 
Hi antagonists did not block this response. 
Ovalbumin antigen caused dose-related release of 
histamine from In vitro guinea pig lung. Dulabh and 
Vickers (56) found that H2 antagonism with cimetidine 
or burimamide potentiated this release. This demonstrates 
the role of H2 receptors in modulating the immune response- 
mediated release of histamine. 
In addition, metiamide or cimetidine potentiated the 
antigen-induced bronchoconstriction in guinea pig lung (56). 
Other investigators have achieved similar results (2, 90). 
It appears that metiamide also potentiates the 
antigen-induced release of histamine in sensitized rhesus 
monkey lung (30, 31). canine lung, bovine lung, and 
monkey skin (30) in vivo. However, Platshon and 
Kaliner (124) were unable to prove that H2 blockade 
potentiated histamine release in the human lung i_n vitro ■ 
H2 antagonism does not potentiate histamine release 
from passively sensitized rat lung (30, 34). This 
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suggests that H2 agonism may not inhibit endogenous 
histamine release in the rat (30)* Holyroyde and Eyre 
(80) showed that H2 blockade actually prevented hist¬ 
amine release in sensitized bovine lung. It is inter¬ 
esting to note that H2 blockade does not, in some ex¬ 
perimental models (30, 33. 88) also enhance SRS-A 
release from sensitized tissues. This is a curious 
result, since SRS-A release is inhibited by increased 
levels of cyclic AMP and H2 agonism increases cyclic 
AMP levels. 
Effect on Histamine Production, Metabolism, 
Uptake, Storage, and Clearance 
Not only does H2 agonism prevent release of 
histamine, it also inhibits production of histamine. 
H2 antagonists induce histidine decarboxylase to pro¬ 
duce histamine (10k, 125)* Histamine metabolism is 
also promoted by H2 receptor agonism and is inhibited 
by H2 antihistamines (67, 107, 125)- Taylor (lkk) 
was unable to show, however, that either the Hi anti¬ 
histamine mepyramine, or the H2 antihistamine burima- 
mide had any effect on histamine methyltransferase, 
the enzyme which is involved in the methylation of 
histamine, the predominant mode of inactivation of 
the mediator. Blockage of the H2 receptor also 
inhibits histamine storage in mast cells (l4, 107). 
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H2 antagonists prevent histamine uptake (3^. 68, 107) 
and delay clearance of histamine from the circulation 
(3^. 133)• 
Effect on Other Participants in the Immune Response 
Increased levels of cyclic AMP, the result of 
H2 agonism, also inhibit T-cell induced cytolysis (14, 
126). H2 agonists in high concentrations will inhibit 
eosinophil migration (14) as well as inhibit lysosomal 
enzyme release from human polymorphonuclear cells (93. 
125). Acting through the H2 receptor, histamine will 
inhibit the production of lymphokines. 
Just as histamine acts upon Ha receptors to promote 
PGF2a release, histamine acts upon K2 receptors to 
promote release of PGE, a prostaglandin which has 
cyclic-AMP-mediated, bronchodilating activity. PGE 
may in turn inhibit further histamine release by acti¬ 
vation of cAMP in mast cells (16). Metiamide can 
antagonize histamine-induced release of PGE. 
In conclusion, histamine released during a hyper¬ 
sensitivity reaction may participate in a number of 
mechanisms to provide feedback inhibition in order to 
limit the severity of the reaction. 
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Histamine, Antihistamines, and the Immune 
Reaction in the Clinical Setting 
Antihistamines as Preventors of the Inflammatory Response 
Although histamine is a major mediator of anaphylaxis, 
antihistamines have not been effective in the complete 
control of this process. Several reasons for this have been 
suggested. Other mediators are involved in the anaphylactic 
response. These include SRS-A, kinins, prostaglandins, 
and serotonin. SRS-A has been shown to be the mediator 
responsible for the late, prolonged phase of broncho- 
constriction in the antigen-challenged human bronchus 
(125). Although H2 receptors seem to be most important 
in inhibition of the inflammatory response, to the effect 
that they cause increased vascular permeability, they 
contribute to the inflammatory process. Classical Ha 
antihistamines have no effect on the H2 receptor contri¬ 
bution to this process. 
Antihistamines nevertheless do have important 
clinical relevance in the modification of the inflam¬ 
matory reaction. Plaut (125) found that cutaneous 
reactivity to compound US/80 could be inhibited by 
combinations of Hi antihistamines and cimetidine. 
He proposes that H2 and H2 receptor blockade might be 
helpful for treating some cutaneous manifestations of 
allergic diseases such as chronic urticaria (125). 
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Similarly, Harvey and Schocket (?8) found that H2 
antihistamines potentiated the effect of Hi antihist¬ 
amines in blocking the cutaneous wheal response, 
although H2 antihistamines alone had no effect. It 
is suggested (78) that H2 receptors are somewhat in¬ 
volved in the cutaneous histamine response. Goadby 
and Little (75) found that metiamide protected against 
anaphylaxis in the guinea pig, a finding which is 
unusual, considering the purported role of H2 receptors 
in modifying the immune response. 
Rocklin (129) noted that in sensitized guinea pigs, 
histamine in concentrations of 10-3M reduced the size 
of a delayed hypersensitivity skin test. This effect 
could be reversed by an H2 antagonist. He proposed 
that histamine suppresses cutaneous delayed hyper¬ 
sensitivity in part, by inhibiting the production and 
proliferation of migration inhibiting factor (MIF). 
H2 antagonists reversed this inhibition of MIF (129). 
In so doing, H2 antagonists such as cimetidine have 
been shown to be of therapeutic value in allowing the 
expression of cutaneous cell-mediated immunity. For 
example, cimetidine is useful in the treatment of 
selected deficiencies in the immunologic response to 
Candida antigen (86). 
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Antihistamines as Potentiators 
of the Inflammatory Response 
H2 antihistamines, by antagozing H2-mediated inhibi¬ 
tion of inflammation, may potentiate anaphylaxis. Dunlop 
and Smith demonstrated (57) that metiamide potentiates 
anaphylactic bronchoconstriction _in vitro . This was 
the observation of Drazen, _et al. (55) v*ho found that 
H2 antihistamines burimamide and metiamide increased 
the severity of immune-initiated anaphylaxis in the 
guinea pig. 4-methylhistamine decreased the severity 
of the reaction (55)- Of note is the fact that cimeti- 
dine, another class of H2 antagonist, had no effect. 
Wolfe, et al. (151) came to the same conclusion 
regarding cimetidine. They were unable to demonstrate 
a prominent modulating role for H2 receptors in immediate 
or delayed skin test reactivity. Krell and Chakrin 
(90) were unable to find that H2 blockade with metiamide 
potentiated antigen-induced or histamine-induced changes 
in dynamic lung compliance or pulmonary resistance in 
the dog at doses up to 16 times the ED^q for inhibition 
of gastric acid secretion. They conclude that insofar 
as the sensitized canine might be a model for human 
asthma, it appears that H2 antihistamines may not be 
deleterious to allergic asthmatics (90). 
While in one study, cimetidine potentiated the 
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anaphylactic response in the guinea pig (56), required 
doses were 100 micromoles per kilogram, a dose between 
50 and 100 times that required to inhibit maximal gastric 
output by 50^ in the rat and dog (14). It is unlikely 
that the results of Dulabh and Vickers (56) can be ex¬ 
tended to conclude that a potential effect of thera¬ 
peutic doses of H2 receptor antihistamines would be to 
cause intensified allergic reactions in man. 
However, a recent case report in the New England 
Journal of Medicine (48), described the appearance 
of a hypersensitivity reaction which coincided with 
the oral administration of cimetidine. The reaction 
disappeared after discontinuance of the H2 antagonist. 
This finding was supported by the work of Avella, 
et al. (9) who found that in patients receiving cimet¬ 
idine, there was a significant enhancement of the 
delayed hypersensitivity response to four common 
antigens as compared to controls. This is most likely 
due to the antagonism of H2 receptor mediated stimu¬ 
lation of suppressor T cell function (9). 
Expecting that H2 blockade would remove inhibition 
of the delayed hypersensitivity reaction, Dale (44) 
noted that metiamide did not exacerbate the tuberculin 
reaction in the guinea pig. She concluded that other 




The Role of Histamine in Asthma 
Introduction 
Asthma may be defined as a disease process 
characterized by an increased reactivity of the 
trachea and bronchi to various stimuli (*0 . This 
leads to reversible narrowing of airways. Asthma is 
marked by increased contraction of bronchial smooth 
muscle and increased secretion of mucous in the bronchial 
tree. Asthma is manifested by the symptoms and signs 
of dyspnea, wheezing, cough, prolonged expiration, 
and responsiveness to bronchodilator drugs. 
Asthmatic airways display hyperreactivity to a 
number of stimuli. These include specific allergens 
such as house dust, animal dander, pollen, and drugs 
(114). Other stimuli include suggestion (81, 97. 131» 
l4o) , smoke, excercise (136), respiratory infections 
(4), and emotional reactions (4). 
The mechanism for the allergic hyperreactivity in 
asthmatics is via the Type I immediate hypersensitivity 
reaction which is mediated by the IgE antibody which 
reacts with surface bound antigen. Asthmatic broncho- 
spasm is also mediated via Type III hypersensitivity, 
a late, gradually appearing immune-complex reaction. 
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The most important mediators of asthmatic broncho- 
spasm are histamine and SRS-A. Other mediators such 
as bradykinin and prostaglandins play a less important 
role. Bronchoconstriction is mediated by chemical 
mediators, as previously discussed, via a rise in intra¬ 
cellular levels of cyclic GMP. This in turn causes a 
rise in intracellular Ca++ levels with subsequent 
activation of contractile proteins. 
In addition to chemical mediators, bronchoconstric- 
tion is promoted by increased parasympathetic tone. 
Cholinergic stimulation similarly causes a rise in 
intracellular calcium ion levels (Ilk). Interaction 
of bronchoconstricting elements with "irritant recep¬ 
tors" causes reflex bronchoconstriction through vagal 
stimulation. Vagally-induced bronchoconstriction can 
not be inhibited by classical Hi antihistamines, although 
it can be prevented by treatment with parasympathetic 
blocking agents such as atropine or ipratropium bro¬ 
mide (11^-0. 
Agonism with 3 2 receptors on respiratory smooth 
muscle causes bronchorelaxation. Neurotransmitters 
which combine with 32 receptors will relax bronchial 
smooth muscle. The mechanism of bronchorelaxation 
is via stimulation of cyclic AMP which causes decreased 
calcium ion levels. This increase in cyclic AMP 
-k?- 

which results from catecholamine stimulation, also 
decreases the antigen-induced release of histamine in 
sensitized lung _in vitro (106). 
Asthmatics may experience disturbances in any of 
several mechanisms which lead to increased bronchial 
activity. They may display hypersensitivity to antigens, 
increased responsiveness to histamine, abnormally active 
parasympathetic tone, or diminished sympathetic (3 2 
receptor) responsiveness (106, 110, 142). The following 
pages will focus on the role of histamine in asthma. 
The Role of Histamine in Asthma 
The findings that histamine causes bronchoconstric- 
tion and is released in immediate hypersensitivity reac¬ 
tions have led to a strong association of asthmatic 
bronchospasm with histamine (117). With regard to 
histamine, asthmatics may experience an increased release 
of histamine in response to bronchoconstricting stimuli 
as compared to healthy humans. 
For example, in addition to the role of vagal 
stimulation in exercise-induced bronchospasm, histamine 
also seems to be involved. Simon, et al. (136) found 
that among some asthmatics, excercise provoked a fall 
in pulmonary function (FEVi). This decline in FEV a 
correlated well with increased levels of histamine in 
the peripheral venous blood. 
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Asthmatics may also have an increased sensitivity 
to the histamine which is released. Indeed, asthmatics 
develop bronchoconstriction in response to lower concen¬ 
trations of inhaled histamine than do normal persons 
(91, 110, 139). This fact is useful in the identifi¬ 
cation of persons with hyperreactive airways (109). 
There is some evidence in the mouse model for asthma, 
that histamine sensitivity may be in part, an inheri¬ 
table trait (l4?). 
In addition, asthmatics differ from normals in 
that asthmatics have detectable levels of histamine 
in their plasma (17) even without antigen challenge. 
Nonasthmatics do not have any detectable level of 
endogenous histamine in their plasma. 
Asthmatics might suffer from an imbalance in the 
numbers of different types of histamine receptors 
which have opposing effects on bronchial smooth muscle. 
This theory is supported by recent experimental evidence. 
Busse and Sosman (26) noted that histamine, acting 
through H2 receptors, inhibits serum-activated zymosan- 
induced lysosomal enzyme release from granulocytes. 
This response parallels a simultaneous increase in 
levels of cyclic AMP. The authors found (26) that 
this Hs-mediated inhibition of lysosomal enzyme release 
is significantly decreased in asthmatics as well as 
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normal volunteers infected with rhinovirus l6 (24). 
This suggests that asthmatics have decreased numbers 
or sensitivity of H2 receptors. Furthermore, viruses 
may exacerbate the asthmatic condition through their 
effect on H2 activity. 
The decreased responsiveness of H2 receptors in 
asthmatics is important. The antigen-antibody reaction 
might initiate a selective increase in cyclic GMP level 
in asthmatics (124). Since the H2 receptor acts to 
control further histamine release from sensitized cells 
as well as acts to stimulate histamine metabolism and 
uptake, diminished H2 reactivity would cause increased 
levels of endogenous histamine. In asthmatics, who 
are sensitive to even minute quantities of histamine, 
this increase in histamine levels would lead to further 
bronchoconstriction. For the same reason, H2 blockade 
in asthmatics would be expected to be more deleterious 
than in non-asthmatics, because the slight increases 
in histamine would effect asthmatics, whose Hi receptor 
are much more sensitive to slight increases in the 
levels of histamine. 
Airway obstruction in asthma is due, in part, 
to inflammatory changes in the bronchi. Granulocytes 
may be found in the respiratory tree in increased 
numbers during bronchial reactivity. Important medi- 
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ators of this inflammatory response are the lysosomal 
enzymes. Decreased inhibition by the H2 receptor of 
these lysosomal enzymes may contribute to the inflam¬ 
matory response in asthmatics (26). It is interesting 
to note that persons with other defects in immune re¬ 
sponsiveness, such as those with atopic eczema, may 
also have diminished H2 receptor-mediated inhibition 
of the inflammatory process (25). 
Some authors, however, have found no difference 
between H2 receptor responsiveness in asthmatics and 
non-asthmatics. Gillespie et al. (73) found no signi¬ 
ficant difference between asthmatics and non-asthmatics 
in the effect of histamine on lymphocyte cAMP levels 
(an H2 receptor-mediated process). 
The finding that asthmatics have decreased H2 
receptor responsiveness is analagous to the decreased 
responsiveness of 32 adrenergic receptors seen in 
asthmatics as compared to non-asthmatics (106, 110, 142). 
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HISTAMINE RECEPTORS IN THE AIRWAYS OF 
HEALTHY, HUMAN SUBJECTS 
Introduction 
While many of the previously described studies 
have provided excellent evidence for the presence of 
histamine Hi and H2 receptors in the airways of manv 
species, there is little evidence for the presence 
of H2 receptors in human airways. Should H2 receptors 
exist in normal or asthmatic airways, and should they 
provide a role in bronchodilation, as in animal models, 
this finding might have important therapetic implica¬ 
tions. For example, H2 receptor agonists might be 
useful as bronchodilators. Furthermore, caution might 
need to be followed in using H2 receptor antagonists 
in persons with compromised respiratory function. 
Evidence to date includes i_n vitro studies on the 
presence of H2 receptors in sensitized human bronchus 
(57. 89). Two recent studies in non-asthmatics (59. 99) 
have found no evidence for the presence of H2 receptors 
in the airways of non-asthmatics. Two recent studies 
(71, 109) provide preliminary evidence that Hi and H2 
receptors are present in asthmatic airways, and H2 
receptors mediate bronchodilation. 
The following experiment describes an investigation 
of the effects of histamine Hi and H2 receptor blockade 
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in the airways of healthy, non-asthmatic, human subjects. 
The goal of the experiment was to provide evidence for 
the presence or absence of Hx and H2 receptors in the 
small airways of normal man. 
Materials and Methods 
Subject Selection 
Subjects were recruited as paid volunteers. They 
gave written, informed cinsent for participation in 
the experiment, as approved bv the Yale University 
School of Medicine Human Investigations Committee. 
Eleven healthy, non-asthmatic subjects (8 males, 
3 females) ranged in age from 18 to 35- The mean age 
was 26.3 - 5-1 years. All had no history of asthma 
or recent respiratory diseases which could simulate 
an asthmatic response to histamine (26, 6c). Baseline 
pulmonary functions were at least 85^ of normal predicted 
values for the group as a whole. (TABLE I) 
Histamine preparation 
Histamine dihydrochloride (Sigma, St. Louis) was prepared 
in normal saline as a stock solution of 128 mg. base 
ml.. Stock solution was kept frozen when not in use. 
Serial dilutions of the stock solution provided 
concentrations of histamine used for the study. Sub¬ 
jects received histamine challenges of 0.1, 2, 6, 8, 
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16 . 32 , 64, and 128 mg. /ml. (9x 10‘4M to 1.15M; pH=? .0 to 3.7). 
Drugs Used 
All drugs were administered single-blindedly. 
Cimetidine 300 mg. (Smith, Kline, and French, Philadelphia) 
is a highly specific H2 receptor antagonist (22). It was 
selected because of its recent wide use in the treatment 
of various illnesses, particularly gastrointestinal 
disorders (149). The dosage of the drug provided a 
blood level of cimetidine of twice that required to 
suppress by 80^, secretion of gastric acid by the 
stomach (149). 
Chlorpheniramine maleate 8 mg. (USV, Tuckahoe), 
an alkylamine derivative, was selected because of its 
negligible sedative and anticholinergic effects as well 
as its high specificity for Hi receptors as compared 
to other Hi antihistamines (119)• 
A lactose placebo dispensed in a pink gelatin cap¬ 
sule (Eli Lilly and Company, Indianapolis) was used. 
Medications were administered orally, after an over¬ 
night fast, li to 2 hours prior to histamine challenge, a 
time designed to coincide with peak levels of each drug 
(127, 130, 149). No side effects of cimetidine, chlorphen¬ 
iramine, or placebo were reported. Since both cimetidine (143, 
149) and chlorpheniramine (122) have very short physiological 
and pharmacological half-lives, the possibility of 
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drug-drug interactions was negligible, since the drugs 
were administered at least 24 hours apart. 
Aerosol Challenge 
Histamine was delivered via a Dautrebande D-30 
nebulizer (45, 46), driven by 20 pounds per square 
inch of compressed air (0.5 ml. liquid nebulized/min.). 
Particles of histamine were thus consistently aerosol¬ 
ized to less than 0.5 microns in diameter. This assured 
deposition of histamine in the respiratory bronchioles 
and lung alveolar spaces. 
Subjects wore a noseclip and inhaled the histamine 
through a mouthpiece attached to a separate, valved 
breathing circuit. Histamine was inhaled for 3° seconds 
by tidal breathing. Tidal breathing controlled against 
the effects of deep inspiration on pulmonary function 
in non-asthmatics (108). Adverse symptoms to inhaled 
histamine at highest challenge doses included headache, 
cough, flushing of the skin, tachycardia, and chest 
tightness. Higher doses of histamine were not given 
to subjects after the onset of adverse symptoms. 
Pulmonary Function Testing 
Histamine induces large airway constriction 
through both direct agonism with Hi receptors, and to 
a lesser extent, by vagal mechanisms. Peripheral 
-55- 

airway constriction is almost entirely the result of 
direct agonism with Hi receptors of smooth muscle 
(8, 47). Keeping in mind the fact that histamine was 
being delivered primarily to small airways, the pulmonary function 
tests selected for this experiment were selected for 
their sensitivity in measuring small airway constriction. 
A particularly sensitive measure of small airways con¬ 
striction is the MEF40(P), the maximum expiratory flow 
at 60 percent below vital capacity on a partial expira¬ 
tory curve (20, 105). This test measures flow during 
the part of expiration which is independent of expira¬ 
tory effort. The flow at 60 percent of vital capacity 
is determined by the static recoil pressure of the lung 
and the flow-resistive properties of small airways 
(20, 105). 
The particular sensitivity of the partial flow- 
volume curve may reflect the absence of the effects 
of a deep inspiration required for the generation of 
maximal expiratory flow volume curves (69. 72, 108). 
All subjects were familiarized with the breathing 
maneuvers and equipment at the beginning of the study. 
Breathing maneuvers were repeated until reproducible 
curves could be obtained. 
Subjects blew into a cardboard tube attached to 
a computerized pneumotachograph-integrator system (148) 
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which calculated flow and volume. The measurements 
were recorded on a Gould x-y recorder (slew rate of 
40 inches per second). The equipment was calibrated 
daily. 
Subjects expired to residual volume, then inspired 
to approximately 50-70% of their vital capacity. While 
wearing a noseclip, the subjects then expired into the 
cardboard tube as fast as possible to residual volume, 
thereby generating the partial expiratory flow-volume 
( PEFV) curve. 
Next, subjects inspired to vital capacity and then 
expired as fast as possible to residual volume, thereby 
generating the maximal expiratory flow-volume (MEFV) 
curve. A programmable marker, set to trigger at 1 
second, permitted identification of the forced expira¬ 
tory volume at 1 second (FEVi). The resultant curves 
allowed measurement of the forced vital capacity (FVC), 
peak expiratory flow rate (PEFR), and maximum expira¬ 
tory flow rate at 60% below vital capacity on the MEFV 
curve (MEF40) and PEFV curve (MEF40(P)). (Figure 1) 
FEVX is a particularly sensitive measure of airway 
obstruction during a relatively effort-independent 




Each day of the experiment, there were controls 
against factors known to influence responses to hista¬ 
mine (87)- Each day, pre-challenge flow-volume maneuvers 
were performed to establish the baseline for the day. 
The baseline FEVa and MEF40(P) for the subjects on each 
day was expressed as a percent of the baseline on Day 1. 
(TABLE II) Histamine challenge was performed at the 
same time of day to control for diurnal variations in 
histamine response (49, 95)- 
Day _!--Histamine Dose Response 
On Day 1, the baseline pulmonary function was 
determined. Prior to each histamine challenge, each 
subject repeated three flow-volume maneuvers to estab¬ 
lish a pre-challenge control value. Starting with 
doses of 0.1 mg./ml. of histamine, subjects received 
a histamine challenge as previously described. Inhala¬ 
tion of histamine was followed immediately by pulmonary 
function testing at 0, 1, 2, 4, 6, and 8 minutes. The 
averages of the first three and second three blows 
were calculated. 
If a subject did not experience a 20% fall in 
MEF40 (P) as compared to pre-challenge control values, 
within the first three minutes, then the next successive 
dose of histamine was administered after a thirty-minute 
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wait. The wait between successive doses of histamine 
challenge was designed to control against any cumula¬ 
tive effect of histamine (8?). Pre-challenge controls 
expressed as a percentage of the baseline for Day 1 
are recorded in TABLE III. 
When a subject experienced a 2C% decline in 
MEF40(P) as compared to pre-challenge control, this 
dosage was referred to as the "threshold" dose. 
(Figure 2) 
Days 2, J, and 4--Premedication With Antihistamines 
On each of Days 2, 3> and 4, subjects were given, 
on successive days, an oral dose of Hi antihistamine 
(chlorpheniramine), H2 antihistamine (cimetidine), 
or placebo (lactose) , if- to 2 hours prior to histamine 
challenge. 
Baseline pulmonary function was determined at the 
beginning of each day. Prior to each histamine challenge, 
each subject established a pre-challenge control value 
as on Day 1. Pre-challenge controls as a percent of 
baseline for Days 2, 3> and 4 are recorded in TABLE IV. 
Each subject received a dose of histamine at one 
dose below the threshold dose as determined on Day 1 
(T-l). Subjects also received a histamine challenge 
at threshold dose (T) and one dose above the threshold 
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(T+l). Each histamine challenge was followed by 
pulmonary function testing at 0, 1, 2, 4, 6, and 
8 minutes after histamine challenge. The averages of 
the first three and second three blows were calculated 
for MEF40(P) and FEV i. The average of the first three 
blows was calculated as a percentage of the pre-challenge 
control.(TABLE V)(Figures 3 and 4) 
Analysis of Data 
The means and standard deviations for the pulmonary 
function tests were calculated. Using this information, 
a t-test for the comparison of two means (58) was used 
to compare changes in daily baseline or pre-challenge 
control pulmonary function, as well as changes in 
pulmonary function following histamine challenge as 
compared to pre-challenge control values. 
Underlying the comparison of the MEF40(P) values, 
is the assumption that the air flow reflected a defined 
lung volume. This could be the case only if total lung 
capacity remained unchanged during histamine provocation. 
Total lung capacity has indeed been shown (20, l4l) to 
remain constant during induced bronchoconstriction in 




Analysis of the baseline FEVi and MEF40(P) for 
each day (TABLE II) shows that pulmonary function did 
not significantly vary from day to day. 
A clear dose response curve (TABLE VI) could be 
generated for histamine inhalation. The effects of 
histamine on pulmonary function for the group became 
significant at 32 mg./ml. for both the MEF40(P) and 
FEVi curves. The MEF40(P) curve was more significant 
than the FEV1 curve at doses of 32 mg./ml. and 64 mg./ 
ml. . (Figure 2, TABLE VII) 
There was a slight cumulative effect of histamine 
on pre-challenge control levels at 64 mg./ml. of hista¬ 
mine. (TABLE III) 
Chlorpheniramine significantly prevented the decline 
in MEF40(P), at threshold doses of histamine, as compared 
to Day 1. Pulmonary function values for placebo and 
cimetidine were not significantly different at threshold 
as compared to Day 1. (TABLE VIII) 
Pretreatment with chlorpheniramine significantly 
protected against the fall in MEF40(P) as compared to 
placebo at doses (T) and (T+l). Significant protection 
of chlorpheniramine against the fall in FEV1 as compared 
to placebo was apparent at dose (T+l). There was no 
significant difference between placebo and cimetidine 
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for either MEF40(P) or FEVi at any test dose of 
histamine. (Figures 3 and 4, TABLES V, VIII, and IX) 
Discussion 
Various conclusions may be drawn from this study. 
It can be seen from the comparison of baseline pulmonary 
function from each day that chlorpheniramine, cimetidine, 
and placebo each had no bronchoconstrictory or broncho- 
dilatory effects on baseline pulmonary function. Popa 
(127) studied the effects of oral and intravenous chlor¬ 
pheniramine in asthmatics. He found that chlorphenir¬ 
amine did improve baseline pulmonary function. However, 
this study examined the effect of chlorpheniramine on 
non-asthmatics. The difference in findings may be due 
to the relative absence of endogenous histamine in non¬ 
asthmatics as compared to asthmatics (1?) in addition 
to the decreased sensitivity of non-asthmatics to the 
little endogenous histamine which may exist (91. 110, 
139). Thus, while chlorpheniramine may block Hi recep¬ 
tors in asthmatics which would otherwise be stimulated 
by histamine, chlorpheniramine blocks receptors in 
non-asthmatics, which, in the absence of exogenous 
histamine provocation, would otherwise not be agonized. 
Subjects could not be excluded from the study if 
baseline pulmonary function varied from day to day, as 
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this variation might be attributed to the effect of 
the drug. Exclusion of these persons might therefore 
skew the results in favor of persons in whom the drugs 
had no effect. 
The finding that baseline pulmonary function did not signifi¬ 
cantly vary daily added, in retrospect, a useful control to 
the study. Benson (15) found that the resting state 
of the airways was an important determinant of bronchial 
reactivity. Thus, if either chlorpheniramine, cimeti- 
dine, or placebo increased the resting bronchomotor 
tone in the airways, they could have potentiated subse¬ 
quent bronchoconstriction due to histamine. 
It may also be concluded that one dose of 3°0 mg. 
of oral cimetidine has no effect on baseline pulmonary 
function in non-asthmatics. It would be premature to 
extend this conclusion to the clinical setting of 
continuous cimetidine use in non-asthmatics. However, 
this finding suggests the possibility of conducting 
such a study which would examine pulmonary function in 
non-asthmatics before, during, and after chronic 
cimetidine use. 
This study confirmed that the methodology used 
can successfully generate a dose response curve for 
inhaled histamine provocation. Furthermore, the useful¬ 
ness of the MEF40(P) pulmonary function test as a 
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sensitive measure of bronchoconstriction has been 
demonstrated. The measurement of MEF40(P) is particularly 
useful in measuring small airways constriction. In 
addition, the Dautrebande D-30 nebulizer is particularly 
useful in delivering small histamine particles to the 
smallest airways. It may thus be concluded that recep¬ 
tors mediating bronchoconstriction, which are stimulated 
by histamine, exist in the small airways of healthy, 
human subjects. 
A small cumulative effect of histamine was observed 
to occur on Day 1 as evidenced by pre-challenge pulmo¬ 
nary function, upon reaching a dose of 64 mg./ml., the 
highest threshold dose of histamine for any subject. 
However, no cumulative response was apparent on Days 
2, 3* and 4. The finding of a cumulative response on 
Day 1 is surprising. Juniper, et al. (8?) found no 
such response after waiting only five minutes between 
successive histamine challenges, although they did 
not challenge anyone with more than 16 mg./ml. of 
histamine. Perhaps the time required to adequately 
clear 32 mg./ml. from the respiratory system, as 
delivered to the airways by the protocol used in this 
study is greater than the thirty minutes which was 
permitted before the 64 mg./ml. challenge. The small 
decline in baseline pulmonary function prior to the 
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64 mg./ml. challenge might also be attributed to the 
general fatigue of the subjects, who spent over two 
hours waiting and who previously performed the pulmonary 
function maneuveur more than for any other test dose. 
Chlorpheniramine had a very significant effect 
in preventing induced bronchoconstriction due to 
histamine inhalation. Blockade of the Hi receptors 
with the oral medication was significantly greater than 
placebo. The difference between chlorpheniramine and 
placebo could be detected at both the threshold and 
superthreshold doses of histamine. As in the histamine 
dose response curve, MEF40(p) Was a more sensitive test 
than FEVi in detecting differences between chlorphenir¬ 
amine and placebo, as well as detecting the protective 
effect of chlorpheniramine as compared to the histamine 
dose response curve. 
Chlorpheniramine did not have a completely protective 
effect against the bronchoconstricting effects of hista¬ 
mine. This may have been due, in part, to incomplete 
antagonism of all the Hi receptors in the small airway 
by the oral medication. Inhaled Ha receptor antagonists, 
such as clemastine (113) have apparently been more 
successful than oral medications in providing Ha 
antagonism in asthmatics. In fact, clemastine (113) 
causes bronchodilation in asthmatics, perhaps by leaving 
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endogenous histamine free to stimulate bronchodilating H2 
receptors. 
Chlorpheniramine is a competitive antagonist of Hj 
receptors. Thus, high concentrations of histamine, such as 
those which may have been by the T+l dose, could displace 
the antagonist from the receptor. 
A small component on the bronchoconstriction due to 
histamine may have been the result of vagally-mediated, reflex 
bronchoconstriction (52). Histamine particles, particularly 
those with a moderately acidic pH among the higher doses, 
may have stimulated irritant receptors, particularly in the 
larger airways (47) to cause bronchoconstriction which can not 
be prevented by Hi antagonism. In this study, parasympatholytic 
agents, such as atropine, may have provided additional protection. 
Unlike inhaled clemastine (113). chlorpheniramine did 
not yield any bronchodilation either at baseline or upon 
histamine challenge. This result does not support the 
presence of H2 receptors in the normal human lung which 
mediate bronchodilation. 
The absence of an H2 receptor-mediated broncho¬ 
dilation at baseline may be explained as due to either 
the absolute deficiency of H2 receptors, or more likely, 
the absence of endogenous histamine in non-asthmatics 
which could bind with H2 receptors. The fact that 
histamine challenge did not yield bronchodilation 
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during Hi receptor blockade, may be due to the absolute 
lack of H2 receptors. It may also be possible, that 
with the oral medication, even at subthreshold levels 
of histamine, there were still an adequate number of 
unbound Hi receptors agonized by histamine to counter 
any effect of H2 agonism. Thus, a net bronchoconstric- 
tion would be observed. 
Further studies in the non-asthmatic might explore 
the possible bronchodilatory effects of an inhaled 
antihistamine on both baseline pulmonary function and 
response to histamine challenge. Smaller doses of 
histamine than those which were used in this study 
might simulate endogenous levels of histamine in the 
asthmatic and agonize any possibly existent H2 receptors 
without displacing Hi antagonists and causing a net 
Hi receptor-mediated bronchoconstriction. Pretreatment 
with an H2 antagonist in addition to an Hi antagonist 
on the same day might remove H2-mediated bronchodilation, 
resulting in a significantly larger net bronchoconstric- 
tion than in pretreatment with only an Hi antagonist. 
No placebo effect was observed. Placebos have 
been reported to influence the amount of bronchocon- 
striction due to histamine provocation (131). However, 
the placebo has to be presented to the subject as a 
substance which has a bronchoconstricting or broncho- 
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dilating effect. Subjects in this study were not 
informed as to what the effects of the drugs might 
be with regard to subsequent histamine challenge. 
Cimetidine was no different than placebo with 
regard to pulmonary finction observed upon histamine 
challenge. Blockade of H2 receptors neither protected 
against or potentiated bronchoconstriction. If H2 
receptors, which mediated bronchoconstriction, existed 
in the lung, then cimetidine would be expected to 
have a protective effect, as was the case with chlor¬ 
pheniramine . 
If H2 receptors which mediate bronchorelaxation 
were successfully anatagonized by cimetidine, then 
subsequent histamine challenge would stimulate only 
Ha receptors. This would promote an even greater 
bronchospasm than that observed with placebo, in which 
case, both Hi and H2 receptors are stimulated. 
The H2 receptor has been implicated, through cyclic 
AMP mechanisms, to have a variety of effects which 
would inhibit the effects of histamine challenge. 
These effects include H2 receptor-mediated inhibition 
of further histamine release (9*0. inhibition of 
histamine production (104, 125). promotion of histamine 
metabolism (67. 107, 125). promotion of histamine 
clearance from the circulation (34, 133). and promotion 
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of histamine uptake by mast cells (3^ » 68, 107). 
Blockade of these effects, particularly the effects 
on metabolism, uptake, and clearance, by cimetidine 
would also potentiate histamine-induced bronchospasm. 
However, cimetidine was not successful in potentiating 
histamine-induced bronchospasm. 
These findings are consistent with the preliminary 
reports of Eiser (59) and Maconochie (99) who also 
found no bronchoconstrictory effects of cimetidine. 
The most likely conclusion to be drawn from the evi¬ 
dence is that H2 receptors do not exist to any signi¬ 
ficant degree in non-asthmatic airways. If H2 receptor 
are present in the lung, the effects of H2 agonism are 
negligible compared to the bronchoconstrictory effects 
of Hi agonism. 
If there are few H2 receptors in the lung, it is 
possible that at the doses of histamine used for this 
experiment, the histamine overcame the competitive 
antagonism by cimetidine for H2 receptor sites in the 
lung. Thus, cimetidine might have been displaced from 
the opportunity to potentiate bronchospasm. At lower 
levels of histamine agonism, H2 blockade might have 
potentiated bronchospasm. While it is difficult to 
measure bronchospasm in non-asthmatics at low levels 
of histamine challenge, asthmatics are much more 
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sensitive to low levels of histamine (91. 110, 139). 
The finding that cimetidine promotes bronchospasm in 
asthmatics (71, 109) may be due to the fact that 
cimetidine is not displaced by the low levels of 
histamine used in the histamine challenges. In addi¬ 
tion, acting through mechanisms which potentiate the 
presence and release of histamine (34, 67, 68, 94, 
104, 125. 133) small levels of additional histamine 
which would not provoke bronchospasm in the non¬ 
asthmatic might potentiate bronchospasm in the sensi¬ 
tive asthmatic. 
It is possible, as has been pointed out by 
Macanochie, et al. (99) that the cimetidine used in 
this study did not achieve adequate levels in the 
lung. Cimetidine levels in human lung following oral 
administration have not been studied. The effects of 
cimetidine on histamine metabolism, uptake and clearance 
have also not been investigated. However, the dosage 
of cimetidine used in this study provided a blood 
level of twice that required to inhibit gastric acid 
secretion in the stomach by 80%. 
Perhaps future studies could investigate the effects 
of an inhaled H2 agonist, such as 4-methylhistamine or 
dimaprit on pulmonary function. Future studies could 
also investigate the effects of an inhaled H2 antagonist, 
-70- 

in hopes of achieving better penetration in the lung 
than with oral administration. 
A possible reason for the findings of this investi¬ 
gation may be the failure of cimetidine to adequately 
antagonize the histamine receptors in the lung which 
mediate bronchodilation. A previous study (66) demon¬ 
strated that cimetidine did not potentiate the depressor 
actions of histamine in tissue in which burimamide and 
metiamide, which belong to a different class of H2 
antagonists, potentiated the depressor effects on carotid 
blood pressure. Similarly, a subclass of H2 receptor 
not antagonized by cimetidine, might be present in the 
human lung. 
Several other studies have demonstrated the 
presence of histamine receptors in the airways of the 
rat, ferret (40), cat (35). horse (37, 39), and rabbit 
(36, 70) which mediate bronchodilation and can be 
agonized by 4-methylhistamine (40), yet which cannot 
be antagonized by conventional H2 antihistamines. 
Perhaps such a class of H3 receptors may exist in human 
lung. 
Histamine was aerosolized so as to reach the smallest 
airways (45, 46). The MEF40(P) pulmonary function test 
is particularly sensitive to small airways constriction 
(20, 105). If H2 receptors in the human lung exist 
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predominantly in the large airways, the protocol of 
this investigation may not have been sensitive enough 
to document any effects of H2 blockade. Regional 
differences in the distribution of H2 receptors has 
been demonstrated in several animal species (14, 64, 
156). For example, H2 histamine receptors are more 
prominent in the central airways than the peripheral 
airways in the guinea pig (156). 
The regional differences in histamine receptor 
distribution may correlate with the physiologic impor¬ 
tance of maintaining the patency of the large airways. 
An alternative study could examine the effects of 
larger aerosolized histamine particles on pulmonary 
flow resistance, a sensitive measure of central resis¬ 
tance (98), in order to more closely investigate the 
presence of H2 receptors in large airways. Atropine 
would have to be used in this proposed protocol, 
because of the relative importance of irritant receptors 
in the large airways. 
In conclusion, the experimental evidence presented 
in this investigation confirms the presence of Hi 
receptors in the airways of healthy human subjects. 
These receptors appear to mediate bronchoconstriction 
and can be successfully antagonized by chlorpheniramine. 
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The role of H2 receptors in healthy human airways, 
as either bronchodilators acting directly on smooth 
muscle or as inhibitors of the presence of histamine, 
appears to be negligible under the conditions of the 
protocol used in this study. Cimetidine did not potentiate 
histamine-induced bronchospasm. The role of H2 receptors 
in asthmatic bronchoconstriction and bronchodilation 
remains a possibility for future investigation. 
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MAXIMAL AND PARTIAL EXPIRATORY FLOW-VOLUME CURVES 































HISTAMINE DOSE RESPONSE AS CHARACTERIZED 
BY TWO MEASUREMENTS OF PULMONARY FUNCTION 





























THE EFFECT OF ANTIHISTAMINES 














THE EFFECT OF ANTIHISTAMINES 

























FVC FEV i FEV 1% 
4.41 3.68 83-9 
0.82 0.69 9-3 
89% 94% 
PEFR mef50% Age 
8.21 4.50 26.3 





BASELINES AT BEGINNING OF DAY 
AS PERCENTAGE OF BASELINE ON DAY 1 
DAY 1 CM CH P 
FEV i 100 99.6 99.8 99.0 










AVERAGE HISTAMINE DOSE-RESPONSE 
PRE-CHALLENGE CONTROLS AS 
PERCENT OF INITIAL BASELINE 
.1 2 4 8 16 32 64 
100 100 98.9 98.1 98.6 99.0 100.7 





PRE-CHALLENGE CONTROLS ON DAYS 2, 3, ANT) 4 
AS PERCENT OF INITIAL BASELINE 
CIMETIDINE 
DOSE T-l T T+l 
FEVa 100 98.45 98.6 
mef40(p) 10O 101 .4 101 .9 
CHLORPHENIRAMINE 
DOSE T-l T T+l 
FEVi 100 IOO.36 100.8 
mef40(p) 100 102.3 98.4 
PLACEBO 
DOSE T-l T T+l 
FEV x 100 99.5 102.0 





THE EFFECT OF PRETREATMENT WITH ANTIHISTAMINE 
UPON SUBSEQUENT RESPONSE TO HISTAMINE 
(Means * Standard Error of the Mean) 
FEV2 
DOSE T-l T T+l 
CIMETIDINE 99.0 93-64 86.0 
±1.13 ±2.79 ±4.30 
CHLORPHENIRAMINE 101 .72 98.91 96.09 
±1 .71 ±1.23 ±2.60 
PLACEBO 101.88 95-75 85-88 
±4.42 ±2.54 ±2.49 
MEF40(P) 
DOSE T-l T T+l 
CIMETIDINE 96.0 79-64 57.80 
±4.26 ±3.70 47.39 
CHLORPHENIRAMINE 99.0 91.45 82.18 
±4.17 ±2.54 ±5.58 
PLACEBO 91.88 78.13 57.88 







HISTAMINE DOSE RESPONSE 
AS PERCENTAGE OF PRE-CHALLENGE CONTROL 
(Means i Standard Error of the Mean) 
.1 2 4 8 16 32 64 







12.65 10 ±1-39 12.01 ±0.73 13-59 12.98 
99.90 97 100.5 94.2 92.0 79-72 73-29 




RESPONSE TO INHALED HISTAMINE 
AS COMPARED TO RESPONSE TO 
0.1 MG./ML. OF INHALED HISTAMINE 
DOSE 4 8 16 32 64 
FEV i NS NS NS p<.0 5 p<.0 5 





COMPARISON OF THE PROTECTIVE EFFECT 
OF CHLORPHENIRAMINE, CIMETIDINE, AND PLACEBO 
UPON SUBSEQUENT RESPONSE TO INHALED HISTAMINE 
AS MEASURED BY MEF40(P) 
DAY 1 
DAY 1 CHLORPHENIRAMINE(CT) CIMETIDINE(CM) PLACEBO 
T-l ■if-**** NS NS NS 




T-l NS NS NS 
T p< .0025 ■*■*•*■*•* pc. 01 pc. 05 
T+l 
CM 
* *■**■*•#■ p<.0005 p< .00 5 
T-l NS NS NS 
T NS p<.01 •a-#**-* NS 
T+l 
P 
* pc.0005 NS 
T-l NS NS NS 
T NS pc.05 NS 
T+l * pc.005 NS 





COMPARISON OF THE PROTECTIVE EFFECT 
OF CHLORPHENIRAMINE, CIMETIDINE, AND PLACEBO 
UPON SUBSEQUENT RESPONSE TO INHALED HISTAMINE 
AS MEASURED BY FEV x 
DAY 1 CHLORPHENIRAMINE(CT) CIMETIDINE(CM) PLACEBO(P) 
DAY 1 
T-l P=.0 7 NS NS 
T p=. 14 NS NS 





O NS NS 
T p =. lb •a-***# p<.05 NS 
T+l pc.001 pc. 05 
CM 
T-l NS NS NS 
T NS p<.05 NS 
T+l * p<.001 *■*■«■■*■* NS 
P 
T-l NS NS NS ■*•■*-*■*■* 
T NS NS pc.05 
T+l * p<.05 pc.001 
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